StockWatch: Investors Unfazed by Illumina’s MiSeq Product Launches, Starboard’s $1B Stake in Pfizer
Investors shrugged as Illumina pressed its case for building on its longtime leadership in next-generation sequencing, judging by how flat the company’s shares fared this past week. And while Wall Street initially seemed upbeat about Starboard’s challenge to Pfizer, lifting its shares 3.5% Wednesday from $29.18 to $30.19, the stock surrendered most of that gain the following day, slipping 3% Thursday to $29.34, then dipping another nearly 1% Friday to $29.16.
